Symbols

LCTX

Lineage Cell·AMEX

--(--)

LCTX fundamentals

LCTX Q4 2025 Earnings

Lineage Cell (LCTX) released its earnings on Mar 5, 2026: revenue was 2.90M (YoY 0.00%), beat estimates; EPS was 0.02 (YoY +200.00%), beat estimates.

Revenue / YoY

2.90M

0.00%

EPS / YoY

0.02

+200.00%

Report date

Mar 5, 2026

LCTX Earnings Call Summary for Q4,2025

OpRegen Momentum: Genentech's 17-site expansion and 3-year visual improvement data highlight program strength, with potential Phase III readiness.
AlloSCOPE Breakthrough: 0.5-liter islet cell production milestone solves industry scale challenge, positioning Lineage for commercial dominance.
Financial Resilience: $55.8M cash runway extended to 2028, with $32M in exercisable warrants offering future liquidity.
Pipeline Expansion: New cell type disclosure imminent, ReSonance hearing loss program advanced to preclinical stage in 1 year.

Earnings

EPS

Revenue

Revenue & Expenses

LCTX has released its 2025 Q4 earnings report, with revenue of 6.61M, reflecting a YoY change of 130.40%, and net profit of 892.00K, showing a YoY change of 127.45%. The Sankey diagram below clearly presents LCTX's revenue sources and cost distribution.

Key Indicators

Lineage Cell (LCTX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Lineage Cell (LCTX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Lineage Cell (LCTX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Lineage Cell (LCTX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown